Benefits
Antioxidant protection of LDL (hydroxytyrosol class evidence)
In a single 16-week placebo-controlled trial in 49 adults with overweight and prediabetes, 15 mg of hydroxytyrosol daily lowered oxidized LDL and other oxidation markers, with no change in blood lipids. That product was not Oli-Ola. The EU authorizes a related claim only for olive oil supplying 5 mg of hydroxytyrosol and its derivatives per 20 g daily.
Facial pigmentation: small pilot, no difference from placebo
In a 90-day double-blind pilot in 42 women with melasma, the oral group took 300 mg capsules of a 3 percent hydroxytyrosol grade of Oli-Ola daily. Pigmentation scores and the melanin index fell from baseline within that group, but the pigmentation score also fell with placebo, neither measure differed from placebo, and 9 of the 42 women dropped out.
Skin elasticity and hydration: unpublished maker trial
Nexira registered a 12-week double-blind trial in 132 women aged 40 to 60 comparing an olive fruit extract, two other botanical preparations and placebo; its main outcome was skin firmness. Nexira reports 800 mg a day of Oli-Ola, 13 percent better elasticity and 12 percent lower water loss, but no firmness result, group sizes or statistics have been published.
Skin explant oxidation marker (laboratory only)
In a maker-funded laboratory model, intestinal cells were exposed to Oli-Ola and the fluid that passed through them was applied to donated human skin; skin malondialdehyde, a lipid oxidation marker, fell by 59 percent. No one swallowed the extract, so this does not show an effect in people.
Mechanism of action
Free radical scavenging by hydroxytyrosol
Hydroxytyrosol and tyrosol are phenolic antioxidants. In people, 15 mg of hydroxytyrosol daily lowered oxidized LDL in a placebo-controlled trial of a different product. For Oli-Ola itself, the antioxidant data come from a laboratory skin explant model, not from people taking it.
Melanin pathway (laboratory rationale)
The authors of the Oli-Ola pigmentation pilot cite laboratory work suggesting that catechols such as hydroxytyrosol compete with L-DOPA at tyrosinase, the enzyme that starts melanin production. This has not been shown to change pigmentation in people taking Oli-Ola: the pilot found no difference from placebo.
Clinical trials
Randomized, double-blind, placebo-controlled pilot with three arms: oral Oli-Ola 300 mg capsules (3 percent hydroxytyrosol, Nexira Health) with a plain cream; a cream with 1 percent of a different olive extract (HydrOlive, 20 percent hydroxytyrosol) with placebo capsules; or placebo capsules with a plain cream, daily for 90 days. All used the same sunscreen. Funded by Brazilian public research agencies; the authors declared no conflicts. Not indexed in PubMed. (Bagatin et al. 2020, Biomedical and Biopharmaceutical Research)
42 women aged 32 to 49 with Fitzpatrick skin types III and IV and melasma on the central face, in Ribeirao Preto, Brazil; 14 per group, of whom 3 per group dropped out and were left out of the analysis.
Between-group comparisons of the pigmentation score (mMASI) and the melanin and erythema indexes found no significant difference from placebo (p > 0.05). Within the oral Oli-Ola group, mMASI was lower than baseline at day 60 (p = 0.0212) and day 90 (p = 0.0008) and the melanin index at day 60 (p = 0.0167), but mMASI also fell within the topical group, and it fell 11 percent with placebo against 22 percent with oral Oli-Ola. Within-group changes do not show an effect of the product, and Nexira's marketing cites the 22 percent figure without the placebo comparison. Side effects were not reported.
Nexira-sponsored, single-centre, randomized, quadruple-blind, placebo-controlled trial with four parallel arms: an olive fruit extract, a clove and immortelle combination, a hibiscus extract, or maltodextrin placebo, as capsules daily for 84 days (completed June 2024). The registry entry does not name the olive extract or its dose; Nexira's own page describes a 12-week double-blind trial in 132 women aged 40 to 60 given 800 mg a day of Oli-Ola (5 percent grade). No results are posted and no paper has been published. (Nexira 2024, ClinicalTrials.gov NCT06254209)
132 women aged 40 to 60 with healthy skin, across all four arms combined.
The registered primary outcome was skin firmness by cutometry; its result has not been disclosed. Nexira's web pages and press releases report 13 percent better skin elasticity versus baseline and placebo, 12 percent lower trans-epidermal water loss, 57 percent of participants reporting fewer imperfections and 87 percent satisfaction for Oli-Ola, plus faded dark spots perceived by 1 in 2 women in a normal-weight subgroup. Group sizes and statistics are not available, so these figures cannot be checked.
Randomized, double-blind, placebo-controlled parallel trial (NCT06295913) of 15 mg hydroxytyrosol daily for 16 weeks; the primary outcome was oxidized LDL. It tested another company's hydroxytyrosol-rich olive extract, reported in trade press as Hytolive, not Oli-Ola; that maker's Genosa I+D is a listed collaborator on the registration. The authors declared no conflicts of interest. (Moratilla-Rivera et al. 2025, Clinical Nutrition)
Adults aged 40 to 70 with overweight and prediabetes; 52 randomized and 49 completed (24 hydroxytyrosol, 25 placebo).
Compared with placebo, hydroxytyrosol lowered oxidized LDL (p = 0.045), protein carbonyls (p = 0.031) and the DNA oxidation marker 8-OHdG (p < 0.01), prevented falls in total antioxidant status and glutathione peroxidase activity (p < 0.01), and lowered IL-6 (p = 0.05). Blood lipids, body measures and lifestyle measures did not change, and no adverse events were observed.